Global Hyperuricemia Market: Overview
Hyperuricemia is condition in which the level of uric acid in the blood increases to abnormally high levels. Various factors are responsible for hyperuricemia, which include insulin resistance, renal failure, obesity and alcohol consumption which is found to be the most prevalent factor. Scientists are still trying to confirm obesity as a predisposing factor for hyperuricemia,
According to data published in National Institute on Alcohol Abuse and Alcoholism, U.S. an average of 17 million U.S. citizens suffered from alcohol use disorder in 2011. In another statistics published by World Health Organization (WHO) global alcohol consumption in 2010 was around 6 liters of pure alcohol per person aged 15 years above. The incidences of alcohol abuse are increasing across the globe and also act as a major contributing factor to disorders such as liver cirrhosis, and hyperuricemia. Approximately 70% of the uric acid produced in the body is filtered by the kidneys, while the remaining amount is eliminated by intestine. In individuals suffering from renal failure, the elimination of uric acid by the kidney decreases, leading to increased uric acid levels in blood. Further, an article published in the Journal of the America College of Cardiology in the year 2012 suggests that hyperuricemia is found to be associated with dyslipidemia of insulin resistance, systemic inflammation, and hepatic steatosis independent of obesity and metabolic syndrome. Another article published in the journal Arthritis Care & Research in 2013 also suggests further confirmation of obesity as a factor leading to hyperuricemia.
However pre diabetes and insulin resistance are found to be one of the factors leading to hyperuricemia. Articles published in Current Opinion in Rheumatology and BMC Cardiovascular Disorders published in 2013 and 2012 have confirmed the factors.
Global Hyperuricemia Market: Trends and Prospects
Various drugs especially cancer drugs are also found to cause hyperuricemia. High level of uric acid in the blood for a prolonged period of time is also a major cause of gout. These factors will increase the prevalence of hyperuricemia as drive the market in the future. Currently ULORIC (febuxostat) manufactured by Takeda Pharmaceuticals is widely prescribed for treating hyperuricemia. However the drug is not prescribed for treatment of high uric acid without a history of gout.
Various clinical trials are carried out by research institutes and companies in order to discover most efficient drug for rearming the disorder. Ardea Biosciences, Inc. is conducting phase 2 clinical trials for testing efficiency of RDEA806 for treatment of hyperuricemia. Hebei Medical University is conducting phase 3 trials to test the hypothesis that prednisone is superior over allopurinol in renal function improvement in heart failure patients with hyperuricemia. TWi Biotechnology, Inc. was awarded with U.S. patent in 2014 for AC – 201 which is effective in treating hyperuricemia. Similar research and development activities will add more products to the market and expand its reach globally. Lesser competition and wide scope for research and development activities have made the market more attractive. As newer drugs receive regulatory approvals, the market is expected to boost in the near future. Due to high cost of branded drugs, the market will have a restricted growth in the regions of Asia Pacific, Latin America, the Middle East and Africa which majorly comprise of under developed and developing economies.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.